Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8934
Title: | Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus |
Authors: | Debove, I.;Paschen, S.;Amstutz, D.;Cardoso, F.;Corvol, J. C.;Fung, Victor S. C.;Lang, A. E.;Martinez Martin, P.;Rodriguez-Oroz, M. C.;Weintraub, D.;Krack, P.;Deuschl, G. |
WSLHD Author: | Fung, Victor S. C. |
Issue Date: | 2024 |
Citation: | Movement Disorders 39(2):235-248, 2024 |
Abstract: | BACKGROUND: Impulse-control and related behavioral disorders (ICBDs) significantly impact the lives of Parkinson's disease (PD) patients and caregivers, with lasting consequences if undiagnosed and untreated. While ICBD pathophysiology and risk factors are well-studied, a standardized severity definition and treatment evidence remain elusive.OBJECTIVE: This work aimed to establish international expert consensus on ICBD treatment strategies. To comprehensively address diverse treatment availabilities, experts from various continents were included.METHODS: From 2021 to 2023, global movement disorders specialists engaged in a Delphi process. A core expert group initiated surveys, involving a larger panel in three iterations, leading to refined severity definitions and treatment pathways.RESULTS: Experts achieved consensus on defining ICBD severity, emphasizing regular PD patient screenings for early detection. General treatment recommendations focused on continuous monitoring, collaboration with significant others, and seeking specialist advice for legal or financial challenges. For mild to severe ICBDs, gradual reduction in dopamine agonists was endorsed, followed by reductions in other PD medications. Second-line treatment strategies included diverse approaches like reversing the last medication change, cognitive behavior therapy, subthalamic nucleus deep brain stimulation, and specific medications like quetiapine, clozapine, and antidepressants. The panel reached consensus on distinct treatment pathways for punding and dopamine dysregulation syndrome, formulating therapy recommendations. Comprehensive discussions addressed management strategies for the exacerbation of either motor or non-motor symptoms following the proposed treatments.CONCLUSION: The consensus offers in-depth insights into ICBD management, presenting clear severity criteria and expert consensus treatment recommendations. The study highlights the critical need for further research to enhance ICBD management. 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. Copyright 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/8934 |
DOI: | https://dx.doi.org/10.1002/mds.29700 |
Journal: | Movement Disorders |
Type: | Journal Article |
Study or Trial: | Review |
Department: | Neurology |
Facility: | Westmead |
Keywords: | Parkinson Disease Consensus Mental Disorders Dopamine Agonists Deep Brain Stimulation Disruptive, Impulse Control, and Conduct Disorders |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.